Reduced-antigen-content diphtheria-tetanus-acellular pertussis (dTpa) vaccine, Boostrix™,
is indicated for booster vaccination of children, adolescents and adults. The original prefilled …

At 60 months post-vaccination, adults (mean age 45.6 years) randomised to receive
combined reduced-antigen-content diphtheria–tetanus and acellular pertussis vaccine …

Background. The recent introduction of acellular pertussis vaccines (Pa) offers the possibility
of booster doses in older children and adults. This can be conveniently accomplished by …

Reduced-antigen, combined diphtheria, tetanus, and acellular pertactin-containing pertussis
vaccine (dTpa; Boostrix™) contains reduced quantities of the same toxoids/antigens found …

Abstract▴ The reduced-antigen combined diphtheria-tetanus-acellular pertussis vaccine
(dTpa) is intended for use as a booster dose in individuals aged≥ 4 years.▴ A single dose …

Abstract▲ Boostrix® US formulation (hereafter referred to as Tdap) is a formulation of
reduced-antigen, combined diphtheria-tetanus-acellular pertussis vaccine, adsorbed onto …

Immunogenicity and reactogenicity of DTPa and reduced antigen dTpa booster vaccines
were compared to a hepatitis A control vaccine in DTPa-primed toddlers aged 18–20 …

Reduced-antigen-content diphtheria–tetanus–acellular-pertussis (dTpa) vaccines are
predominantly recommended for once-in-a-lifetime use. A second dTpa (Boostrix™ …

Pertussis continues to circulate in Chinese communities and older children, adolescents and
adults are sources of infection for unprotected infants. Two studies conducted in Jiangsu …

Background. Booster vaccination against tetanus and diphtheria at 10-year intervals is
commonly recommended. Reduced antigen content diphtheria and tetanus toxoids and …